UNSPSC 51101636: Azanidazole

This classification denotes an antiprotozoal agent with the molecular formula C10H10N6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YP2Y0DRX4S, chemically known as 2-pyrimidinamine, 4-(2-(1-methyl-5-nitro-1h-imidazol-2-yl)ethenyl)-, (e)- but generally known as azanidazole, which bears US NIH Compound Identifier 6436171. European Medicines Agency schedules Azanidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05635MIG.

UNSPSC 51101636 Azanidazole (Commodity) shows minimal recent state and local procurement activity under its nominal scope, with no opportunities for the named chemical itself appearing in current solicitation records. The code's abstract designation—a specific antiprotozoal pharmaceutical ingredient—does not align with what state and local governments are actually purchasing in the recent opportunities tagged to it. Instead, the tagged solicitations span broad pharmaceutical procurement categories including naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals through cooperative purchasing vehicles. These opportunities reflect state and local demand for finished pharmaceutical products, OTC goods, and emergency medical supplies rather than raw chemical ingredients or specialized antiprotozoals. The issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal fire and rescue services (City of Tampa), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP).

Recent opportunities span Florida, Texas, Minnesota, and multi-state cooperative arrangements. The City of Tampa issued an IFB on March 25, 2026 (due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000 and a small local business enterprise (SLBE) set-aside including a 5% bid discount not to exceed $10,000; MMCAP, administered by the Minnesota Department of Administration, issued an RFP (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with evaluations weighted heavily on price competitiveness (75 percent); Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023—note the date discrepancy in the source) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; and the Texas Health and Human Services Commission issued an RFI in March 2026 (response due April 3, 2026) exploring vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. The code shows no distinct concentration among repeat buyers or geographic regions, with activity distributed across single-jurisdiction health and emergency procurement and broad multi-state cooperative agreements.